Face to face with the IFPMA's Dr Harvey Bale: "Coordination with attitude"
This article was originally published in Scrip
He has now retired as director-general of theIFPMA, the international federation of pharmaceutical manufacturers & associations. But just before he left, I met Dr Harvey Bale for a chat in a central London hotel. He was in fact waiting for me in the lobby of the hotel five minutes before the allotted time, looking dapper and expectant.
You may also be interested in...
Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
European biotech Pharvaris has received series C funding to support its novel potential therapy for hereditary angioedema, in a competitive sector of drug development.